Primary spinal cord glioblastoma multiforme treated with temozolomide

Silvia Hernández-Durán, Amade Bregy, Ashish H. Shah, Simon Hanft, Ricardo J Komotar, Glen Manzano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms "glioblastoma" and "primary spinal cord neoplasms, intramedullary". We stratified the papers into two groups according to the use of TMZ, and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The TMZ subgroup contained nine articles and a total of 19 patients with primary SC GBM who were treated with adjuvant TMZ. The non-TMZ group consisted of 19 articles including 45 patients who underwent other treatment modalities. The TMZ subgroup had an overall survival of 16 months, compared to the non-TMZ group with a median overall survival of 10 months. The difference between these two groups was not statistically significant (p = 0.57). While this review did not demonstrate a statistically significant difference in long term survival between patients with SC GBM treated with TMZ versus those not treated with TMZ, a slightly longer survival time was seen in the TMZ group. The small number of patients is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of TMZ in the treatment of SC GBM.

Original languageEnglish (US)
Pages (from-to)1877-1882
Number of pages6
JournalJournal of Clinical Neuroscience
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

temozolomide
Glioblastoma
Spinal Cord
Survival
Medical Subject Headings
Spinal Cord Neoplasms
Therapeutics

Keywords

  • Glioblastoma multiforme
  • Intramedullary tumor
  • Neoplasm
  • Spinal cord

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Primary spinal cord glioblastoma multiforme treated with temozolomide. / Hernández-Durán, Silvia; Bregy, Amade; Shah, Ashish H.; Hanft, Simon; Komotar, Ricardo J; Manzano, Glen.

In: Journal of Clinical Neuroscience, Vol. 22, No. 12, 01.12.2015, p. 1877-1882.

Research output: Contribution to journalArticle

Hernández-Durán, Silvia ; Bregy, Amade ; Shah, Ashish H. ; Hanft, Simon ; Komotar, Ricardo J ; Manzano, Glen. / Primary spinal cord glioblastoma multiforme treated with temozolomide. In: Journal of Clinical Neuroscience. 2015 ; Vol. 22, No. 12. pp. 1877-1882.
@article{18eeb381752c4909b99a92006adba07f,
title = "Primary spinal cord glioblastoma multiforme treated with temozolomide",
abstract = "Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms {"}glioblastoma{"} and {"}primary spinal cord neoplasms, intramedullary{"}. We stratified the papers into two groups according to the use of TMZ, and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The TMZ subgroup contained nine articles and a total of 19 patients with primary SC GBM who were treated with adjuvant TMZ. The non-TMZ group consisted of 19 articles including 45 patients who underwent other treatment modalities. The TMZ subgroup had an overall survival of 16 months, compared to the non-TMZ group with a median overall survival of 10 months. The difference between these two groups was not statistically significant (p = 0.57). While this review did not demonstrate a statistically significant difference in long term survival between patients with SC GBM treated with TMZ versus those not treated with TMZ, a slightly longer survival time was seen in the TMZ group. The small number of patients is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of TMZ in the treatment of SC GBM.",
keywords = "Glioblastoma multiforme, Intramedullary tumor, Neoplasm, Spinal cord",
author = "Silvia Hern{\'a}ndez-Dur{\'a}n and Amade Bregy and Shah, {Ashish H.} and Simon Hanft and Komotar, {Ricardo J} and Glen Manzano",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.jocn.2015.04.017",
language = "English (US)",
volume = "22",
pages = "1877--1882",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "12",

}

TY - JOUR

T1 - Primary spinal cord glioblastoma multiforme treated with temozolomide

AU - Hernández-Durán, Silvia

AU - Bregy, Amade

AU - Shah, Ashish H.

AU - Hanft, Simon

AU - Komotar, Ricardo J

AU - Manzano, Glen

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms "glioblastoma" and "primary spinal cord neoplasms, intramedullary". We stratified the papers into two groups according to the use of TMZ, and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The TMZ subgroup contained nine articles and a total of 19 patients with primary SC GBM who were treated with adjuvant TMZ. The non-TMZ group consisted of 19 articles including 45 patients who underwent other treatment modalities. The TMZ subgroup had an overall survival of 16 months, compared to the non-TMZ group with a median overall survival of 10 months. The difference between these two groups was not statistically significant (p = 0.57). While this review did not demonstrate a statistically significant difference in long term survival between patients with SC GBM treated with TMZ versus those not treated with TMZ, a slightly longer survival time was seen in the TMZ group. The small number of patients is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of TMZ in the treatment of SC GBM.

AB - Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms "glioblastoma" and "primary spinal cord neoplasms, intramedullary". We stratified the papers into two groups according to the use of TMZ, and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The TMZ subgroup contained nine articles and a total of 19 patients with primary SC GBM who were treated with adjuvant TMZ. The non-TMZ group consisted of 19 articles including 45 patients who underwent other treatment modalities. The TMZ subgroup had an overall survival of 16 months, compared to the non-TMZ group with a median overall survival of 10 months. The difference between these two groups was not statistically significant (p = 0.57). While this review did not demonstrate a statistically significant difference in long term survival between patients with SC GBM treated with TMZ versus those not treated with TMZ, a slightly longer survival time was seen in the TMZ group. The small number of patients is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of TMZ in the treatment of SC GBM.

KW - Glioblastoma multiforme

KW - Intramedullary tumor

KW - Neoplasm

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=84948686072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948686072&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2015.04.017

DO - 10.1016/j.jocn.2015.04.017

M3 - Article

C2 - 26601809

AN - SCOPUS:84948686072

VL - 22

SP - 1877

EP - 1882

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 12

ER -